Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 307

1.

Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.

Ren J, Nichols C, Bird L, Chamberlain P, Weaver K, Short S, Stuart DI, Stammers DK.

J Mol Biol. 2001 Sep 28;312(4):795-805.

PMID:
11575933
2.

Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.

Ren J, Nichols CE, Chamberlain PP, Weaver KL, Short SA, Stammers DK.

J Mol Biol. 2004 Feb 20;336(3):569-78.

PMID:
15095972
3.

Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.

Das K, Ding J, Hsiou Y, Clark AD Jr, Moereels H, Koymans L, Andries K, Pauwels R, Janssen PA, Boyer PL, Clark P, Smith RH Jr, Kroeger Smith MB, Michejda CJ, Hughes SH, Arnold E.

J Mol Biol. 1996 Dec 20;264(5):1085-100.

PMID:
9000632
4.

Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.

Ren J, Nichols CE, Stamp A, Chamberlain PP, Ferris R, Weaver KL, Short SA, Stammers DK.

FEBS J. 2006 Aug;273(16):3850-60.

5.

The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.

Hsiou Y, Ding J, Das K, Clark AD Jr, Boyer PL, Lewi P, Janssen PA, Kleim JP, Rösner M, Hughes SH, Arnold E.

J Mol Biol. 2001 Jun 1;309(2):437-45.

PMID:
11371163
6.

Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.

Ren J, Stammers DK.

Virus Res. 2008 Jun;134(1-2):157-70. doi: 10.1016/j.virusres.2007.12.018. Epub 2008 Mar 3. Review.

PMID:
18313784
7.

Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases.

Ren J, Nichols CE, Chamberlain PP, Weaver KL, Short SA, Chan JH, Kleim JP, Stammers DK.

J Med Chem. 2007 May 17;50(10):2301-9. Epub 2007 Apr 19.

PMID:
17441703
8.

Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.

Hsiou Y, Das K, Ding J, Clark AD Jr, Kleim JP, Rösner M, Winkler I, Riess G, Hughes SH, Arnold E.

J Mol Biol. 1998 Nov 27;284(2):313-23.

PMID:
9813120
9.

Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.

Ren J, Milton J, Weaver KL, Short SA, Stuart DI, Stammers DK.

Structure. 2000 Oct 15;8(10):1089-94.

10.

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.

Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PA, Arnold E.

J Mol Biol. 1994 Oct 28;243(3):369-87. Review.

PMID:
7525966
11.

Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.

Balzarini J.

Curr Top Med Chem. 2004;4(9):921-44. Review. Erratum in: Curr Top Med Chem. 2004;4(16):1825.

PMID:
15134549
12.

Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.

Zhou Z, Madrid M, Evanseck JD, Madura JD.

J Am Chem Soc. 2005 Dec 14;127(49):17253-60.

PMID:
16332074
13.

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.

Hopkins AL, Ren J, Milton J, Hazen RJ, Chan JH, Stuart DI, Stammers DK.

J Med Chem. 2004 Nov 18;47(24):5912-22.

PMID:
15537346
14.

Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution.

Ding J, Das K, Tantillo C, Zhang W, Clark AD Jr, Jessen S, Lu X, Hsiou Y, Jacobo-Molina A, Andries K, et al.

Structure. 1995 Apr 15;3(4):365-79.

PMID:
7542140
15.
16.

Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.

Himmel DM, Das K, Clark AD Jr, Hughes SH, Benjahad A, Oumouch S, Guillemont J, Coupa S, Poncelet A, Csoka I, Meyer C, Andries K, Nguyen CH, Grierson DS, Arnold E.

J Med Chem. 2005 Dec 1;48(24):7582-91.

PMID:
16302798
17.
18.

Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives.

Ren J, Esnouf RM, Hopkins AL, Warren J, Balzarini J, Stuart DI, Stammers DK.

Biochemistry. 1998 Oct 13;37(41):14394-403.

PMID:
9772165
19.

[Non-nucleoside reverse transcriptase inhibitors].

Joly V, Yeni P.

Ann Med Interne (Paris). 2000 Jun;151(4):260-7. Review. French.

PMID:
10922953
20.

Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.

Das K, Sarafianos SG, Clark AD Jr, Boyer PL, Hughes SH, Arnold E.

J Mol Biol. 2007 Jan 5;365(1):77-89. Epub 2006 Sep 15.

PMID:
17056061

Supplemental Content

Support Center